ArticleOncology2026
Impact of Tyrosine Kinase Inhibitors on Estimated Glomerular Filtration Rate in Chronic Myeloid Leukemia Patients.
Article in Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: Tyrosine kinase inhibitors (TKIs) are the cornerstone of therapy for chronic myeloid leukemia (CML). Although nephrotoxicity has been reported, existing evidence remains inconsistent, with limited data from the Gulf region. This study aimed to evaluate the impact of TKIs on renal function among patients with CML treated at Hamad Medical Corporation (HMC), Qatar.
methodsThis retrospective, single-center study included adults with CML who received a TKI between 2016 and 2023. The primary outcome was the change in estimated glomerular filtration rate (eGFR) over time. Secondary outcomes included acute kidney injury (AKI), chronic kidney disease (CKD) and the need for dialysis. Repeated-measures analysis of variance was used to assess unadjusted eGFR trends. Linear mixed-effects modeling was used to assess longitudinal eGFR trends while adjusting for baseline comorbidities.
resultsA total of 209 patients were followed for a median of 69.3 months (IQR, 39.4-117.8). Imatinib was the most frequently prescribed TKI (n = 136, 65.1%), followed by dasatinib (n = 39, 18.7%) and nilotinib (n = 34, 16.3%). The mean baseline eGFR was 93.8 mL/min/1.73 m2 (SD 26.3) and showed no significant decline at 3 months (p = 0.498), 3 years (p = 0.112), or 8 years (p = 0.297). However, among dasatinib-treated patients, eGFR significantly decreased from 87.5 (SD 16.7) to 76.8 (SD 11.4) over 3 years (p = 0.042). Multivariate mixed-effects modeling revealed that this reduction was confounded by hypertension (p < 0.001). After adjusting for comorbidities, no significant difference in eGFR decline was observed between the TKI groups. AKI occurred in 17 (8.1%) patients, CKD in 4 (1.9%), and none required dialysis. No significant differences were observed across TKI types.
conclusionRenal function remained largely stable during long-term TKI therapy. Initial declines to dasatinib were largely comorbidity-driven, pointing to the need for cardiovascular risk assessment in this population. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.